BetterLife Pharma Q2 2027 Earnings Report

BetterLife Pharma EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

BetterLife Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

BetterLife Pharma Announcement Details

• Quarter: Q2 2027
• Date: 9/29/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

BetterLife Pharma (OTCMKTS:BETRF) is a Canadian biotechnology company focused on developing novel treatments for mental health and neurological conditions. Its research programs are centered on pharmaceutical compounds derived from or inspired by psychedelic substances, with the goal of creating therapies that may offer therapeutic benefits without the hallucinogenic effects associated with some traditional psychedelics.

The company’s development programs have included BETR-001, a synthetic derivative of lysergic acid diethylamide (LSD) being studied for potential applications in depression and other neuropsychiatric disorders, and BETR-002, an ibogaine-derived compound being investigated for substance-use disorders and related conditions. BetterLife has also pursued research involving pain and other central nervous system indications. These programs remain subject to preclinical and clinical development, regulatory review and approval.

BetterLife Pharma is headquartered in Canada and has conducted research and development activities through relationships with scientific, clinical and regulatory organizations. The company has been led by Fahar Merchant, who has served as its president and chief executive officer. Information about its product candidates and corporate activities may change as development programs advance.